NCT06680206View on ClinicalTrials.gov

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

CompletedOBSERVATIONAL
Enrollment

1,363

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

November 20, 2024

Study Completion Date

November 20, 2024

Conditions
Migraine
Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06680206 - Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey | Biotech Hunter | Biotech Hunter